The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Ligand Pharmaceuticals Inc
SWB:LGDN
|
US |
|
Y
|
Yokogawa Electric Corp
F:YKE
|
JP |
|
C
|
China Longyuan Power Group Corp Ltd
F:6WX
|
CN |
|
S
|
Societe Generale SA
XMUN:SGE
|
FR |
|
A
|
Adecco Group AG
XHAM:ADI1
|
CH |
|
I
|
International Graphite Ltd
ASX:IG6
|
AU |
|
Goldman Sachs Group Inc
NYSE:GS
|
US |
|
Friedman Industries Inc
F:X36
|
US |
|
H
|
Hysan Development Co Ltd
OTC:HYSNY
|
HK |
|
BLIS Technologies Ltd
NZX:BLT
|
NZ |
|
Verbrec Ltd
ASX:VBC
|
AU |
|
H
|
HELLENiQ ENERGY Holdings SA
ATHEX:ELPE
|
GR |
|
FFRI Security Inc
TSE:3692
|
JP |
|
Saipem SpA
MIL:SPM
|
IT |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
US |
|
C
|
China Yuchai International Ltd
SWB:CYD
|
SG |
|
P
|
Pegasystems Inc
F:PEA
|
US |
|
L
|
Lumentum Holdings Inc
SWB:LU2
|
US |
|
Nokia Oyj
OMXH:NOKIA
|
FI |
|
Coca-Cola Bottlers Japan Holdings Inc
F:CCW
|
JP |
|
Singapore Post Ltd
OTC:SPSTY
|
SG |
|
H
|
Heineken Holding NV
F:4H5
|
NL |
|
S
|
Saipem SpA
F:SPEA
|
IT |
|
H
|
Hi Special Purpose Acquisition Co VIII
KOSDAQ:450050
|
KR |
Ligand Pharmaceuticals Inc (LGDN)’s 12-month stock price forecast through November 2027 has a consensus target of €318.56, implying 19% upside. The forecast is based on price targets from 14 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
LGDN is 318.56 EUR with a low forecast of 222.61 EUR and a high forecast of 380.4 EUR.
Over the last 13 years, the compound annual growth rate for Revenue has been 16%. The projected CAGR for the next 8 years is 19%.
Over the last 13 years, the compound annual growth rate for Gross Profit has been 16%. The projected CAGR for the next 7 years is 21%.
The compound annual growth rate for Pre-Tax Income over the next 3 years is 32%.
The compound annual growth rate for Net Income over the next 7 years is 26%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more